Recently, Meja et al. [55] demonstrated the synergistic cytotoxicity of a combination of AKT and PIM inhibitors in AML, with convergence on inhibition of Myc, MCL-1, and BAD. This evidence concerns the gene MCL1 and acute myeloid leukemia.